Vaxcyte to Release Phase 3 Data on 31-Valent Pneumococcal Vaccine

Vaxcyte, Inc. (Nasdaq: PCVX) announced it will present topline results from OPUS-1, its pivotal adult Phase 3 clinical trial, during a webcast and conference call scheduled for October 5, 2026, at 8:00 a.m. ET. The San Carlos, California-based clinical-stage vaccine company said the event will focus on data evaluating the safety, tolerability, and immunogenicity of its lead vaccine candidate.

At the center of the disclosure is VAX-31, a 31-valent pneumococcal conjugate vaccine candidate. The compound is designed to prevent invasive pneumococcal disease and pneumococcal pneumonia, conditions caused by the bacterium Streptococcus pneumoniae that carry significant morbidity and mortality risk, particularly among adults.

Read more Monteverde & Associates Probes Four Mergers for Shareholder Rights →

The OPUS-1 trial represents a critical regulatory milestone for Vaxcyte. Topline Phase 3 data from a pivotal adult study typically form the foundation of a biologics license application submitted to the U.S. Food and Drug Administration, placing the market closely watched for signals of efficacy and competitive positioning relative to existing pneumococcal vaccines.

Vaxcyte's VAX-31 candidate covers more serotypes than any currently approved pneumococcal conjugate vaccine on the U.S. market, a distinction the company has cited as a potential differentiator in a field dominated by established players. The breadth of serotype coverage is a key factor regulators and payers assess when evaluating next-generation pneumococcal vaccines.

Continue reading at GlobeNewswire - Industry News on Financial Services.